BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Villani R, Monami M, Di Cosimo F, Fioravanti G, Mannucci E, Vendemiale G, Serviddio G. Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis. J Viral Hepat 2019;26:1249-56. [PMID: 31243849 DOI: 10.1111/jvh.13169] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Yen HH, Su PY, Liu IL, Zeng YY, Huang SP, Hsu YC, Yang CW, Chen YY. Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients. PeerJ 2021;9:e10944. [PMID: 33777520 DOI: 10.7717/peerj.10944] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Scaglione V, Mazzitelli M, Costa C, Pisani V, Greco G, Serapide F, Lionello R, La Gamba V, Marascio N, Trecarichi EM, Torti C. Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy). Medicina (Kaunas) 2020;56:E101. [PMID: 32121135 DOI: 10.3390/medicina56030101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Uchida D, Takaki A, Oyama A, Adachi T, Wada N, Onishi H, Okada H. Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma. Nutrients 2020;12:E1576. [PMID: 32481552 DOI: 10.3390/nu12061576] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
4 Nagaoki Y, Imamura M, Teraoka Y, Morio K, Fujino H, Ono A, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Hayes CN, Chayama K, Aikata H. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. Hepatol Res 2020;50:1222-33. [PMID: 32767446 DOI: 10.1111/hepr.13554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Amoros-Reboredo P, Soy D, Hernandez-Hernandez M, Lens S, Mestres C. Anticholinergic Burden and Safety Outcomes in Older Patients with Chronic Hepatitis C: A Retrospective Cohort Study. Int J Environ Res Public Health 2020;17:E3776. [PMID: 32466526 DOI: 10.3390/ijerph17113776] [Reference Citation Analysis]
6 Xia H, Zhang Y, Zaongo SD, Liang J, Gong X, Hu Y, Ma P, Wang F. Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis. Ann Transl Med 2021;9:847. [PMID: 34164481 DOI: 10.21037/atm-21-1297] [Reference Citation Analysis]
7 Parmar P, Shafran SD, Borgia SM, Doucette K, Cooper CL. Hepatitis C direct-acting antiviral outcomes in patients 75 years and older. JGH Open 2021;5:253-7. [PMID: 33553664 DOI: 10.1002/jgh3.12480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Yuri Y, Nishikawa H, Enomoto H, Yoh K, Iwata Y, Sakai Y, Kishino K, Ikeda N, Takashima T, Aizawa N, Takata R, Hasegawa K, Ishii N, Nishimura T, Iijima H, Nishiguchi S. Impact of Sustained Virological Response for Gastroesophageal Varices in Hepatitis-C-Virus-Related Liver Cirrhosis. J Clin Med 2019;9:E95. [PMID: 31905953 DOI: 10.3390/jcm9010095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]